UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
JAMA ophthalmology, ISSN 2168-6165, 2014, Volume 132, Issue 7, pp. 851 - 858
Life Sciences & Biomedicine | Ophthalmology | Science & Technology | Eyelid Neoplasms - diagnosis | Lymphoma, Follicular - therapy | Humans | Middle Aged | Lymphoma, Follicular - diagnosis | Male | Antineoplastic Agents - therapeutic use | Lacrimal Apparatus Diseases - therapy | Eye Neoplasms - therapy | Orbital Neoplasms - therapy | Aged, 80 and over | Adult | Female | Retrospective Studies | Biomarkers, Tumor - analysis | Lymphoma, Follicular - mortality | Survival Rate | Combined Modality Therapy | Conjunctival Neoplasms - therapy | Eyelid Neoplasms - therapy | Disease-Free Survival | Eye Neoplasms - diagnosis | Lacrimal Apparatus Diseases - mortality | Eye Neoplasms - mortality | Lacrimal Apparatus Diseases - diagnosis | Proton Therapy | Biopsy | Internationality | Conjunctival Neoplasms - mortality | Orbital Neoplasms - diagnosis | Neoplasm Proteins - analysis | Aged | Orbital Neoplasms - mortality | Neoplasm Staging | Eyelid Neoplasms - mortality | Cohort Studies | Conjunctival Neoplasms - diagnosis
Journal Article
Best practice & research. Clinical haematology, ISSN 1521-6926, 2011, Volume 24, Issue 2, pp. 147 - 163
Hematology, Oncology and Palliative Medicine | DLBCL | follicular lymphoma | transformation | MYC | transplantation | Life Sciences & Biomedicine | Hematology | Science & Technology | Lymphoma, Follicular - therapy | Prognosis | Humans | Salvage Therapy | Transplantation, Autologous | Lymphoma, Large B-Cell, Diffuse - etiology | Burkitt Lymphoma - mortality | Burkitt Lymphoma - pathology | Stem Cell Transplantation | Lymphoma, Large B-Cell, Diffuse - therapy | Lymphoma, Follicular - genetics | Cell Transformation, Neoplastic - genetics | Burkitt Lymphoma - genetics | Lymphoma, Follicular - complications | Burkitt Lymphoma - therapy | Lymphoma, Large B-Cell, Diffuse - pathology | Biomarkers, Tumor - analysis | Lymphoma, Follicular - pathology | Lymphoma, Follicular - mortality | Burkitt Lymphoma - etiology | Disease Progression | Lymphoma, Large B-Cell, Diffuse - mortality | Disease-Free Survival | Biopsy | Chromosome Aberrations | Mutation | Cell Transformation, Neoplastic - pathology | Lymphoma, Large B-Cell, Diffuse - genetics | Biomarkers, Tumor - biosynthesis | Research | Non-Hodgkin's lymphomas | Oncology, Experimental | Cancer | Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 10/2017, Volume 377, Issue 14, pp. 1331 - 1344
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antibodies, Monoclonal, Humanized - adverse effects | Lymphoma, Follicular - drug therapy | Nausea - chemically induced | Humans | Middle Aged | Immunologic Factors - administration & dosage | Kaplan-Meier Estimate | Lymphoma, Follicular - mortality | Induction Chemotherapy | Male | Antineoplastic Agents - administration & dosage | Rituximab - administration & dosage | Disease-Free Survival | Antibodies, Monoclonal, Humanized - administration & dosage | Antineoplastic Agents - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Leukopenia - chemically induced | Aged, 80 and over | Adult | Female | Aged | Immunologic Factors - adverse effects | Rituximab - adverse effects | Patient outcomes | Outcome and process assessment (Health Care) | Reports | Lymphomas | Drug therapy | Observations | Methods | Medical research | Gallium | Rituximab | Cytotoxicity | Nausea | Lymphoma | Cancer therapies | Survival | Studies | Chemotherapy | CD20 antigen | Death | Drug dosages | Neutropenia | Index Medicus | Abridged Index Medicus
Journal Article
Clinical cancer research, ISSN 1078-0432, 06/2014, Volume 20, Issue 11, pp. 2862 - 2872
Life Sciences & Biomedicine | Oncology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Antineoplastic agents | Pharmacology. Drug treatments | Immunohistochemistry | Prognosis | Dendritic Cells, Follicular - metabolism | Humans | Middle Aged | Male | Lipopolysaccharide Receptors - metabolism | T-Lymphocytes - metabolism | Aged, 80 and over | Biomarkers, Tumor - metabolism | Adult | Female | T-Lymphocytes - pathology | Biomarkers, Tumor - analysis | Lymphoma, Follicular - pathology | Kaplan-Meier Estimate | Proportional Hazards Models | Lymphoma, Follicular - mortality | Programmed Cell Death 1 Receptor - metabolism | Lipopolysaccharide Receptors - immunology | Cell Transformation, Neoplastic - metabolism | Tumor Microenvironment - immunology | Cell Transformation, Neoplastic - immunology | Dendritic Cells, Follicular - immunology | Lymphoma, Follicular - immunology | Dendritic Cells, Follicular - pathology | T-Lymphocytes - immunology | Aged | Programmed Cell Death 1 Receptor - immunology | Cell Transformation, Neoplastic - pathology | Biomarkers, Tumor - immunology | Index Medicus | CD14 | tumor microenvironment | follicular lymphoma | PD1 | time to transformation
Journal Article
Blood, ISSN 0006-4971, 2004, Volume 104, Issue 5, pp. 1258 - 1265
Life Sciences & Biomedicine | Hematology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Multivariate Analysis | Lymphoma, Follicular - therapy | Age Distribution | Prognosis | Humans | Middle Aged | Risk Factors | Lymphoma, Follicular - mortality | Male | Survival Analysis | Adult | Female | Aged | Index Medicus | Abridged Index Medicus | Life Sciences | Other
Journal Article
British journal of haematology, ISSN 0007-1048, 07/2015, Volume 170, Issue 1, pp. 85 - 95
elderly patients | follicular lymphoma | elderly lymphoma | chemotherapy | rituximab | Follicular lymphoma | Rituximab | Elderly lymphoma | Chemotherapy | Elderly patients | Life Sciences & Biomedicine | Hematology | Science & Technology | United States - epidemiology | Lymphoma, Follicular - therapy | Prognosis | Prospective Studies | Lymphoma, Follicular - pathology | Humans | Middle Aged | Lymphoma, Follicular - mortality | Male | Treatment Outcome | Young Adult | Disease-Free Survival | Lymphoma, Follicular - epidemiology | Aged, 80 and over | Adult | Female | Aged | Cohort Studies | Analysis | Mortality | Lymphomas | Health aspects | Epidemiology | Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 09/2018, Volume 379, Issue 10, pp. 934 - 947
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Thalidomide - adverse effects | Skin Diseases - chemically induced | Lymphoma, Follicular - drug therapy | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lymphoma, Follicular - mortality | Male | Survival Rate | Thalidomide - administration & dosage | Rituximab - administration & dosage | Disease-Free Survival | Thalidomide - analogs & derivatives | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Aged, 80 and over | Adult | Female | Aged | Neutropenia - chemically induced | Rituximab - adverse effects | Chemotherapy | Usage | Lymphomas | Drug therapy | Cancer | Fees & charges | Lymphocytes B | Immunomodulation | Immunotherapy | Advisors | Rituximab | Clinical medicine | Patients | Lymphoma | Neutropenia | Apoptosis | Index Medicus | Abridged Index Medicus | Life Sciences
Journal Article
Cancer, ISSN 0008-543X, 10/2017, Volume 123, Issue 19, pp. 3709 - 3716
follicular lymphoma | mortality | standard mortality ratio | Life Sciences & Biomedicine | Oncology | Science & Technology | Confidence Intervals | Lymphoma, Follicular - drug therapy | Prognosis | Prospective Studies | Age Factors | Humans | Middle Aged | Kaplan-Meier Estimate | Lymphoma, Follicular - mortality | Male | Antineoplastic Agents - therapeutic use | Case-Control Studies | Cause of Death | Disease-Free Survival | Rituximab - therapeutic use | Time Factors | Spain - epidemiology | Sex Factors | Adult | Female | Young adults | Statistical analysis | Mortality | Sex | Population studies | Lymphoma | Survival | Patients | Confidence intervals | Population | Death | Adults | Age | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
European journal of cancer (1990), ISSN 0959-8049, 2017, Volume 76, pp. 216 - 225
Hematology, Oncology and Palliative Medicine | Follicular lymphoma | Rituximab | Maintenance | Meta-analysis | Life Sciences & Biomedicine | Oncology | Science & Technology | Immunocompromised Host - immunology | Doxorubicin - therapeutic use | Multivariate Analysis | Cyclophosphamide - administration & dosage | Lymphoma, Follicular - drug therapy | Humans | Middle Aged | Induction Chemotherapy | Male | Antineoplastic Agents - therapeutic use | Cyclophosphamide - therapeutic use | Infection - etiology | Young Adult | Rituximab - therapeutic use | Infection - epidemiology | Aged, 80 and over | Vincristine - administration & dosage | Adult | Female | Maintenance Chemotherapy | Prednisone - administration & dosage | Proportional Hazards Models | Lymphoma, Follicular - mortality | Survival Rate | Randomized Controlled Trials as Topic | Rituximab - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - therapeutic use | Aged | Prednisone - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Medical policy | Patient outcomes | Analysis | Oncology, Experimental | Lymphomas | Research | Epidemiology | Cancer | Therapy | Data analysis | Randomization | Clinical trials | Data processing | Infections | Lymphoma | Patients | Survival | Subgroups | Index Medicus
Journal Article